scispace - formally typeset
T

Timokratis Karamitros

Researcher at Pasteur Institute

Publications -  55
Citations -  757

Timokratis Karamitros is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 12, co-authored 43 publications receiving 394 citations. Previous affiliations of Timokratis Karamitros include Athens State University & National and Kapodistrian University of Athens.

Papers
More filters
Journal ArticleDOI

SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies.

TL;DR: The isolated SNVs and genomic rearrangements reflect the intra-patient capacity of the polymorphic quasispecies, allowing immunological escape of the virus, offering resistance to anti-viral drugs and affecting the sensitivity of the molecular diagnostics assays.
Journal ArticleDOI

Studying severe long COVID to understand post-infectious disorders beyond COVID-19

Petter Brodin, +102 more
- 05 Apr 2022 - 
Journal ArticleDOI

A novel method for the multiplexed target enrichment of MinION next generation sequencing libraries using PCR-generated baits

TL;DR: By capturing genomic fragments, which contain the target sequences, the authors recover reads extending targeted regions and thus can be used for the determination of potentially unknown flanking sequences and for the first time a standardized method for target enrichment in MinION platform.
Journal ArticleDOI

De Novo Assembly of Human Herpes Virus Type 1 (HHV-1) Genome, Mining of Non-Canonical Structures and Detection of Novel Drug-Resistance Mutations Using Short- and Long-Read Next Generation Sequencing Technologies.

TL;DR: A hybrid genome assembly protocol is employed using data from two sequencing technologies: the short-read Roche 454 and the long-read Oxford Nanopore MinION sequencers to improve the assembly of accurate, full-length HHV-1 genomes.
Journal ArticleDOI

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Paul Bastard, +362 more
- 14 Jun 2022 - 
TL;DR: Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.